Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Amtech Systems | ASYS | Nov 22, 2024 | 5.75 | +0.70 |
Amylyx Pharmaceuticals | AMLX | Nov 22, 2024 | 5.27 | +1.54 |
AN2 Therapeutics | ANTX | Nov 22, 2024 | 1.34 | +8.94 |
Analog Devices | ADI | Nov 22, 2024 | 214.59 | +0.29 |
AnaptysBio | ANAB | Nov 22, 2024 | 22.27 | +5.20 |
Anavex Life Sciences | AVXL | Nov 22, 2024 | 9.11 | +1.00 |
Andretti Acquisition II | POLE | Nov 22, 2024 | 9.96 | 0.00 |
Andretti Acquisition II Unit | POLEU | Nov 22, 2024 | 10.01 | 0.00 |
Anebulo Pharmaceuticals | ANEB | Nov 22, 2024 | 1.46 | -2.67 |
ANEW Medical | WENA | Nov 22, 2024 | 0.73 | 0.00 |
Angel Oak Financial Strategies | FINS | Nov 22, 2024 | 12.63 | +0.56 |
Angel Oak Mortgage REIT | AOMR | Nov 22, 2024 | 9.55 | +1.60 |
Anghami | ANGH | Nov 22, 2024 | 0.77 | +6.81 |
Angi A | ANGI | Nov 22, 2024 | 1.97 | +0.51 |
AngioDynamics | ANGO | Nov 22, 2024 | 6.83 | -1.73 |
Anglogold Ashanti | AU | Nov 22, 2024 | 25.95 | +2.98 |
Anheuser-Busch InBev ADR | BUD | Nov 22, 2024 | 54.73 | +0.07 |
ANI Pharmaceuticals | ANIP | Nov 22, 2024 | 56.91 | +1.88 |
Anika Therapeutics | ANIK | Nov 22, 2024 | 16.97 | -2.64 |
Anixa Biosciences | ANIX | Nov 22, 2024 | 3.20 | +4.58 |
Annaly Capital Management | NLY | Nov 22, 2024 | 19.81 | +0.15 |
Annaly Capital Management F Pref | NLY-F | Nov 22, 2024 | 25.80 | -0.50 |
Annaly Capital Management G Pref | NLY-G | Nov 22, 2024 | 25.53 | -0.04 |
Annaly Capital Management I Pref | NLY-I | Nov 22, 2024 | 25.80 | -0.21 |
Annexon | ANNX | Nov 22, 2024 | 5.14 | -0.58 |
Annovis Bio | ANVS | Nov 22, 2024 | 6.65 | -2.06 |
ANSYS | ANSS | Nov 22, 2024 | 350.00 | +0.30 |
Antelope Enterprise | AEHL | Nov 22, 2024 | 0.26 | +0.91 |
Anterix | ATEX | Nov 22, 2024 | 33.72 | +1.47 |
Antero Midstream | AM | Nov 22, 2024 | 15.77 | -0.06 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.